Why did Novo Nordisk stock fall so sharply this week?

Management guided 2026 revenue down 5–13% due to U.S. pricing pressure, which hit sentiment and drove a 27% weekly slide. Discounts, tougher payer negotiations, and competition weighed on outlook confidence. Later, legal and FDA headlines improved, sparking a Friday rebound, but investors still want clearer signs that pricing pressure will ease.

How do the FDA and Hims headlines affect Novo Nordisk?

Novo said it would fight the Hims Wegovy pill, and the FDA signalled tougher action against potentially unauthorized semaglutide copies. Both are supportive for brand protection and could limit copycat supply. Still, these actions do not remove core pricing pressure from payers and rebates, which remains the primary earnings swing factor.

What technical levels matter for near-term trading?

Momentum pushed into overbought territory (RSI ~75.8) after the bounce, while price remains below the 50‑ and 200‑day averages. That mix often leads to choppy sessions. Traders in Switzerland may prefer staggered buys, tight stops, and limit orders, especially around litigation or FDA updates that can trigger gap moves.

How does Eli Lilly competition influence the outlook?

Eli Lilly has strong growth and a Buy‑leaning analyst view, supporting competitive pressure on share and pricing. Its richer valuation reflects high expectations. If Lilly’s momentum and capacity stay strong, Novo Nordisk stock may need legal wins, better supply, and steadier net prices to re‑rate. Watch prescriptions and payer updates closely.

Global Market Insights

NVO Stock Today: After 27% slide, Hims fight and FDA support — February 9

ByDanny Kontos February 9, 2026February 9, 2026

Novo Nordisk stock is back in focus after a 27% weekly slide and a sharp 9% Friday rebound. Management guided 2026 revenue down 5–13% on pricing pressure, then vowed to stop Hims’ low‑cost Wegovy pill as the FDA signalled tougher action on unauthorized semaglutide copies. For Swiss investors, the setup mixes regulatory support with intense competition from Eli Lilly and a volatile tape. We break down what moved the shares, near‑term risks, and how to position from Switzerland.